Last Price
19.61
Today's Change
+0.615 (3.23%)
Day's Change
19.05 - 19.86
Trading Volume
603,112
Overview
Market Cap
2 Billion
Shares Outstanding
123 Million
Avg Volume
503,793
Avg Price (50 Days)
15.64
Avg Price (200 Days)
13.36
PE Ratio
18.04
EPS
1.09
Earnings Announcement
25-Feb-2026
Previous Close
19.00
Open
19.20
Day's Range
19.05 - 19.86
Year Range
8.61 - 19.86
Trading Volume
604,286
Price Change Highlight
1 Day Change
3.50%
5 Day Change
13.54%
1 Month Change
19.33%
3 Month Change
39.96%
6 Month Change
38.49%
Ytd Change
60.53%
1 Year Change
24.86%
3 Year Change
242.00%
5 Year Change
1448.43%
10 Year Change
980.49%
Max Change
244.40%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Discussions
Be the first to like this.
Showing 0 of 0 comments
Post a Comment
Latest Videos
Apps
Top Articles
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
{uid}
{comment}
Just now